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Abstract This report describes an outbreak of Clostridium
difficile infection (CDI) in a nephrology ward in 2012, caused
by the fluoroquinolone- and clindamycin-resistant polymerase
chain reaction (PCR) ribotype 027 strains. An increase in the
number of cases of diarrhoea was noted among patients
hospitalised between 26 November 2012 and 17 December
2012 in a hospital in North Poland. Eight patients were on
haemodialysis in the outpatient dialysis facility, while one
patient was receiving peritoneal dialysis. The 027 strain could
be detected in eight haemodialysis patients. One strain, isolat-
ed from the patient receiving peritoneal dialysis, belonged to
PCR ribotype 001. In this study, we documented the first
outbreak of CDI caused by a fluoroquinolone-resistant
(FQR) C. difficile PCR ribotype 027 strain in Polish dialysis
patients.
Introduction
Clostridium difficile infection (CDI) is the most common
cause of infections in healthcare facilities. The clinical mani-
festations of CDI range from asymptomatic colonisation to
toxic megacolon, which has a high risk of mortality [1]. The
three main risk factors for CDI include antibiotic exposure,
higher age (65 years and above) and prolonged hospitalisation
[2, 3]. Additional risk factors include cancer, haematopoietic
stem cell transplant (HSCT), co-morbidities associated with
immunosuppression, use of gastric acid-reducing drugs, ad-
mission to the intensive care unit, use of nasogastric tubes and
inflammatory bowel diseases [4–7]. Patients with kidney dis-
ease are also at an increased risk of developing CDI and
represent an especially vulnerable group of patients [8–10].
C. difficile NAP1/BI/027 strains have been reported to be
aetiological agents of severe infections in the USA, Canada
and Europe [11]. Recently, fluoroquinolones (FQ) have been
linked to CDI, particularly those caused by polymerase chain
reaction (PCR) ribotype 027 [12]. In the present study, we
describe the epidemiology of CDI as well as the clinical and
microbiological data of dialysis patients hospitalised in the
nephrology ward of a hospital in Poland, with diarrhoea,
caused by the PCR ribotype 027 strain.
Materials and methods
Patients
The current study was retrospective in nature, usingC. difficile
isolated from stool samples that were collected and stored
when an outbreak was suspected in the nephrology ward.
Diagnostic testing of CDI in the surveyed ward was per-
formed only upon the physician’s request. The study was
conducted at the 620-bed Provincial Hospital (PH), located
in North Poland. In 2012, the incidence of CDI at the hospital
was 4.5/10,000 patient-days (results not shown). Between 1
January 2012 and 31 December 2012, CDI was suspected in
96 symptomatic patients. Of these, 53 tested positive for
C. difficile toxins A/B. The CDI-positive patients were
hospitalised in different wards. Between 26 November 2012
and 17 December 2012, a high incidence of diarrhoea was
observed in the 32-bed nephrology unit. These cases included
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nine dialysis patients with diarrhoea. Our study focused only
on patients hospitalised in the nephrology ward who were
receiving dialysis in the outpatient haemodialysis facility.
Definitions
Diarrhoea was defined on the basis of well-known criteria [13,
14]. According to the European Centre for Disease Prevention
and Control (ECDC), CDI can be classified into two types:
healthcare-associated CDI, which usually occurs in a hospital
after 48 h of admission, and community-associated CDI [15].
A severe case of CDI is defined by fever (>38.5 °C), de-
creased kidney function, high leukocyte count (>15×109
cells/L) or colonic wall thickening revealed by a computed
tomography (CT) scan [15]. Recurrent CDI is diagnosed when
CDI re-occurs within 8 weeks of the onset of a previous
episode, provided the symptoms from the previous episode
resolved after the completion of initial treatment. An outbreak
of CDI is defined as two or more cases related in time and
place over a defined period (28 days), based on the date of
onset of the first case. In this study, a possible CDI outbreak
was identified based on the occurrence of three cases within
30 days, a departure from the normal pattern [16].
Collection of demographic and clinical data
Medical records of the patients were studied for the presence
of clinical symptoms of CDI. Data, including information on
patient demographics, age, sex, admission type, diagnoses,
length of stay, type of dialysis, use of antibiotics, type of
discharge, recurrences and mortality, were obtained for 26
November 2012 through 17 December 2012. Stool character
and frequency, and abdominal pain were also monitored. The
characterisation of dialysis patients with diarrhoea due to
C. difficile is shown in Table 1.
Microbiological methods
Detection of C. difficile toxin and culture of C. difficile strains
CDI in patients who developed diarrhoea was diagnosed by an
immune-enzymatic assay for glutamate dehydrogenase
(GDH; TechLab®, Inc., USA). In samples that tested positive
in the GDH assay, CDI was confirmed using the C. difficile
TOX A/B Test II™ kit (TechLab®, Inc., USA) and the detec-
tion of toxigenicC. difficile in culture.C. difficilewas cultured
from faecal samples using selective CLO Agar (bioMérieux
SA;Marcy l’Etoile, France). After incubation at 35 °C for 48 h
under anaerobic conditions, isolates were confirmed to be
C. difficile on the basis of well-known criteria. All
C. difficile strains were frozen at −70 °C in a Microbank™
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C. difficile isolates from the dialysis patients were collected
for further analysis.
Real-time (RT)-PCR and PCR ribotyping
All C. difficile strains were sent to the Anaerobe Laboratory
(AL) inWarsaw and tested for genetic markers of toxigenicity
using the Xpert CD assay (Cepheid; Sunnyvale, CA, USA).
The Xpert CD assay can be used to detect toxigenicC. difficile
strains and identify the C. difficile NAP1/BI/027 strain. RT-
PCR was performed to detect the tcdB, cdtA and cdtB genes
(binary toxin genes), and a deletion in the tcdC gene (encodes
a negative regulator of toxin A/B production). PCR ribotyping
was performed as described by Stubbs et al. [17]. Binary
toxin-producing control strains belonging to the Cardiff-
ECDC reference strain collection were provided by Jon
Brazier (Anaerobe Reference Laboratory, Cardiff, UK) and
Ed Kuijper (Leiden University Medical Center, Leiden, The
Netherlands), and consisted of R8637 (PCR ribotype 019),
R5989 (PCR ribotype 023), R10456 (PCR ribotype 056) and
strains from PCR ribotypes 045, 078, 027 and 176. The
banding patterns obtained for the C. difficile strains were
compared with those obtained for the reference strains.
Antimicrobial susceptibility testing
C. difficile strains were grown on Columbia Agar plates
(bioMérieux SA, Marcy l’Etoile, France) and subsequent
suspensions were adjusted to an optical density of 1 McF at
900 nm using a bioMérieux ATB 1550 densitometer and
streaked on the surface of Brucella Agar plates. Etests
(bioMérieux SA, Marcy l’Etoile, France) were placed on each
plate and these contained the following antibiotic gradients:
clindamycin (CL), erythromycin (EM), ciprofloxacin (CI),
moxifloxacin (MX), metronidazole (MTZ) and vancomycin
(VA). The plates were incubated under anaerobic conditions at
37 °C for 48 h, according to the manufacturer’s instructions.
The Clinical and Laboratory Standards Institute (CLSI) rec-
ommendations were used to define antibiotic resistance [18].
Quality control strains (Bacteroides fragilis NCTC 11295,
Bacteroides thetaiotaomicron ATCC 29741, Escherichia coli
ATCC 25922 and Staphylococcus aureus ATCC 25923) were
included in all experiments.
Environmental decontamination and extended cleaning
programme
Chlorine bleach was used to clean the sanitary facilities in
rooms occupied by patients diagnosed with CDI.
Indomethacin and Octenisept were used to clean all medical
equipment and furniture. Sanitary ware and hand-contact sur-
faces were cleaned on a daily basis until post-outbreak to
maintain high standards of hygiene. An additional terminal
clean with the hydrogen peroxide vapour (HPV) decontami-
nation technology was completed to eliminate any spores left
behind in the environment. Adjacent rooms received a full
final cleansing upon discharge of CDI-positive patients.
Results
Epidemiological and clinical findings
CDI was observed sporadically among patients hospitalised in
the nephrology unit between January 2012 and October 2012.
Only seven cases of CDI were confirmed during this period.
Between 26 November 2012 and 17 December 2012, an
increased incidence of CDI was observed among dialysis
patients hospitalised in the nephrology unit. The demographic
and clinical data are presented in Table 1. The outbreak
involved nine patients (five women and four men) in total,
whose ages ranged from 52 to 89 years (with a median age of
70.5 years). Watery diarrhoea was observed in all patients, and
was the major clinical manifestation of CDI. Three patients
developed recurrent CDI. Two patients died of complications
due to CDI, yielding a mortality rate of 22 % (2/9).
History of outbreak
Initially, two cases of CDI were detected in the nephrology
unit. The first patient was admitted to the internal department
of cardiovascular diabetology on 15November. Subsequently,
the patient was transferred to the nephrology unit. Since his
risk of acquiring C. difficile was high, he was placed under
isolation. CDI was diagnosed on 26 November. Patient 2 was
admitted on 14 November. CDI was diagnosed after 14 days
of hospitalisation. A history of the symptoms of CDI among
all dialysis patients hospitalised in the nephrology unit is
shown in Fig. 1.
Microbiological analysis
Of the nine C. difficile isolates, eight contained the tcdB gene,
the binary toxin genes (cdtA and cdtB) and a deletion in the
tcdC gene, and one strain possessed the tcdB gene. All eight
isolates positive binary toxin genes were recognised by the
Xpert assay as belonging to the PCR ribotype 027 strain of
C. difficile. PCR ribotyping classified the nine C. difficile
isolates into two ribotypes: 027 (n=8) and 001 (n=1).
Susceptibility testing was performed for all strains. All nine
strains were found to be resistant to CI [minimum inhibitory
concentration (MIC)≥32mg/L], while the eight PCR ribotype
027 strains were resistant to MX (MIC≥32 mg/L). Only type
001 was susceptible to all the other antibiotics. The MIC of
CL was 0.38–6 mg/L, while that of EM was 0.75–256 mg/L.
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All PCR ribotype 027 strains were resistant to EM. Nine
strains were susceptible to MTZ (MIC range 0.094–
0.38 mg/L) and VA (MIC range 0.25–0.5 mg/L).
Discussion
We describe the first outbreak of CDI caused by the
C. difficile PCR ribotype 027 strain in dialysis patients in
Poland. In an earlier study, 175 C. difficile strains were
isolated from patients hospitalised in a teaching hospital
in Warsaw during 2005–2006. Of these, only one isolate
belonged to PCR ribotype 027 [19]. This ribotype was not
observed in Poland until 2008. In the period 2008–2010,
outbreaks of antibiotic-associated diarrhoea occurred in
three different hospitals in Poland [20]. We concluded that
outbreaks of CDI associated with hypervirulent strains be-
longing to PCR ribotype 027 occurred in hospitals in
Poland in 2008–2010.
All patients with diarrhoea were promptly identified
and isolated. Strict isolation procedures remained in place
for 30 days after the last identified case. All symptomatic
patients remained in isolation with dedicated toilets and
shower facilities until discharge, regardless of symptoms.
In an effort to reduce the incidence of CDI, the hospital
used accelerated hydrogen peroxide as the hospital disin-
fectant. Accelerated hydrogen peroxide has been shown to
inactivate C difficile spores within a 15-min window [21,
22]. This ward was then disinfected with non-buffered
hypochlorite, after which the outbreak ended. Fawley
et al. compared the effects of five different cleaning
agents on epidemic and non-epidemic C. difficile strains
[23]. Their study showed that only chlorine-based germi-
cides were able to inactivate C. difficile spores. Martinez
et al. support the use of chlorine-based disinfectants for
preventing the transmission of C. difficile [24]. The im-
plementation of strict infection-control precautions, anti-
microbial stewardship and enhanced environmental
cleaning are key components in managing a C. difficile
outbreak successfully. The outbreak at PH was controlled
successfully by terminal cleaning of the ward and rein-
forcement of infection-control precautions.
Our findings suggest that dialysis patients who are treat-
ed with antimicrobial agents are at a risk of developing
CDI. The outbreak at PH was controlled successfully. Our
report emphasises the importance of monitoring CDIs and
the early identification of symptomatic patients to prevent
the spread of infection.
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Fig. 1 A history of symptoms of CDI among all dialysis patients hospitalised in the nephrology unit
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